益佰制药：收到贵州省药品监督管理局《暂停生产、销售通知书》

Core Viewpoint - Yibai Pharmaceutical has received a suspension notice from the Guizhou Provincial Drug Administration, leading to the halt of production and sales of its pediatric cough syrup due to regulatory non-compliance issues identified during an inspection [1] Company Summary - The suspension notice cites deficiencies such as incomplete record-keeping and unreliable electronic data recording [1] - The company has stated that the revenue contribution from the pediatric cough syrup from 2021 to 2024 is relatively small, and the suspension is not expected to significantly impact overall performance [1]